COMP <GO>
LFVN vs RANI // ENTERPRISE SCALE & MARKET CAP
Lifevantage Corporation (Delaware) (NASDAQ) VS. Rani Therapeutics Holdings Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: LFVN 8
— RANI 2
▲ ENTERPRISE SCALE & MARKET CAP LEADER: RANI
LAST: $5.87 (-0.17%) • MKT CAP: $73.9M
market-cap
$73.9M
LAST: $0.55 (-6.47%) • MKT CAP: $76.9M
market-cap
$76.9M
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LFVN VS. RANI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LFVN | RANI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 80.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.20% | -35.00% | +64.20 | LFVN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 14.22% | -22.28% | +36.50 | LFVN | /fcf-yield <GO> |
| Operating Margin | 5.30% | -60.00% | +65.30 | LFVN | /operating-margins <GO> |
| Net Profit Margin | 4.30% | -60.00% | +64.30 | LFVN | /net-margins <GO> |
| Revenue Growth (YoY) | 14.20% | 58.90% | -44.70 | RANI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.80% | 0.00% | +2.80 | LFVN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.98 | 0.20 | +3.78 | LFVN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | LFVN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.2 | 27.2 | +16.00 | LFVN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.3x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $73.9M | $76.9M | -$3.0M | RANI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LFVN REV | RANI REV | LFVN GROSS % | RANI GROSS % | LFVN FCF | RANI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $228.5M | $1.6M | 80.4% | — | $10.5M | -$18.8M |
| FY 2024 | $200.2M | $1.0M | 79.3% | — | $10.0M | -$35.8M |
| FY 2023 | $213.4M | $185.1M | — | — | $6.8M | -$51.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LFVN // BETA —
RANI // BETA —